irinotecan has been researched along with Carcinoma, Endometrioid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Perrone, E; Ratner, E; Santin, AD; Scambia, G; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B | 1 |
| Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Shimizu, Y | 1 |
1 review(s) available for irinotecan and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
3 other study(ies) available for irinotecan and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Endometrioid; Cell Adhesion Molecules; Cell Differentiation; Cell Line, Tumor; Cell Survival; Endometrial Neoplasms; Female; Humans; Immunoconjugates; Immunohistochemistry; Irinotecan; Mice; Mice, SCID; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2020 |
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |